PMID: 15230149Jul 3, 2004Paper

Sibutramine in treatment of obesity. Therapeutic premises in patients with essential hypertension, diabetes, hyperlipidemia

Przegla̧d lekarski
Marek RajzerKalina Kawecka-Jaszcz

Abstract

Obesity is the one of the fundamental problems in societies of the highly developed countries. In the Framingham study almost linear dependence between cardiovascular mortality and overweight was proven. Moreover, obesity often coexists with different illnesses, such as type 2 diabetes, myocardial ischaemia, essential hypertension, dyslipidemia, arteriosclerosis, renal insufficiency, degenerative changes of joints, cholelithiasis, or some neoplasms. Among methods of treatment of obesity the most known and safe is the low calories content diet. In pharmacotherapy of obesity two medications of new generation i.e. sibutramin and orlistat make up basis at present. The present study is concentrated onto Sibutramin, which acts in the central nervous system. Authors introduce mechanisms of action of the medicine, its participation in termogenesis as well as therapeutic effectiveness. Special attention is dedicated for clinical situations in which decrease of body mass is the key element of therapy, that is essential hypertension, diabetes and hyperlipidemia.

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.